Gut microbiome may be causing Osteoarthritis in obese patients

Published On 2018-04-22 13:50 GMT   |   Update On 2018-04-22 13:50 GMT

Bacteria present in the intestine called gut microbiome could be the reason behind arthritis and joint pain that affects people who are obese.


Osteoarthritis, a common side effect of obesity, is the greatest cause of disability in the US, affecting 31 million people.Osteoarthritis (OA) affects about 4-6% of adult population and is mentioned as one of the top 5 chronic diseases in India. It is a common, age-related, chronic and slowly progressive joint disorder which ultimately leads to joint failure


Researchers at the University of Rochester Medical Center provided the first evidence that bacteria present in the gut could play a vital role to cause osteoarthritis.


Bacteria present in the intestine called gut microbiome could be the reason behind arthritis and joint pain that affects people who are obese.




Michael Zuscik and his colleagues fed mice a high-fat diet akin to a Western 'cheeseburger and milkshake' diet.


Just 12 weeks of the high fat diet made mice obese and diabetic, nearly doubling their body fat percentage compared to mice fed a low fat, healthy diet. Their colons were dominated by pro-inflammatory bacteria, and almost completely lacked certain beneficial, probiotic bacteria, like the common yogurt additive Bifidobateria.


The changes in the gut microbiomes of the mice coincided with signs of body-wide inflammation, including in their knees where the researchers induced osteoarthritis with a meniscal tear, a common athletic injury known to cause osteoarthritis. Compared to lean mice, osteoarthritis progressed much more quickly in the obese mice, with nearly all of their cartilage disappearing within 12 weeks of the tear.


"Cartilage is both a cushion and lubricant, supporting friction-free joint movements," said Zuscik. "When you lose that, it's bone on bone, rock on rock. It's the end of the line and you have to replace the whole joint. Preventing that from happening is what we, as osteoarthritis researchers, strive to do -- to keep that cartilage."


The effects of obesity on gut bacteria, inflammation, and osteoarthritis were completely prevented when the high fat diet of obese mice was supplemented with a common prebiotic,called oligofructose. The knee cartilage of obese mice who ate the oligofructose supplement was indistinguishable from that of the lean mice.


Prebiotics, like oligofructose, cannot be digested by rodents or humans, but they are welcome treats for certain types of beneficial gut bacteria, like Bifidobacteria. Colonies of those bacteria chowed down and grew, taking over the guts of obese mice and crowding out bad actors, like pro-inflammatory bacteria. This, in turn, decreased systemic inflammation and slowed cartilage breakdown in the mice's osteoarthritic knees.


Oligofructose even made the obese mice less diabetic, but there was one thing the dietary supplement didn't change: body weight.


Obese mice who were given oligofructose remained obese, bearing the same load on their joints, yet their joints were healthier. Just reducing inflammation was enough to protect joint cartilage from degeneration, supporting the idea that inflammation -- not biomechanical forces -- drive osteoarthritis and joint degeneration.


"That reinforces the idea that osteoarthritis is another secondary complication of obesity -- just like diabetes, heart disease, and stroke, which all have inflammation as part of their cause," said Mooney. "Perhaps, they all share a similar root, and the microbiome might be that common root."


Though mouse and human microbiomes are different, the bacteria that protected mice from obesity-related osteoarthritis may differ from the bacteria that could help humans.


"There are no treatments that can slow progression of osteoarthritis and definitely nothing reverses it," said first author Eric Schott. "But this study sets the stage to develop therapies that target the microbiome and actually treat the disease."


For further reference log on to: http://10.1172/jci.insight.95997

 

Article Source : With inputs from JCI Insight

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News